

EuroIntervention

<u>Title:</u> Increased mortality among patients with higher right ventricular volumes: Volumetric analysis of pre-trans-catheter aortic valve replacement CT Angiography.

Authors: Zach Rozenbaum, M.D; Eva Maret, M.D; Lilian Lax, M.D; Haim Shmilovich, M.D; Ariel Finkelstein, M.D; Arie Steinvil, M.D; Amir Halkin, M.D; Shmuel Banai, M.D; Dotan Cohen, M.D; Yan Topilsky, M.D; Shlomo Berliner, M.D, PhD; Dominik Fleischmann, M.D; Galit Aviram, M.D

DOI: 10.4244/EIJ-D-19-00651

tervention Citation: Rozenbaum Z, Maret E, Lax L, Shmilovich H, Finkelstein A, Steinvil A, Halkin A, Banai S, Cohen D, Topilsky Y, Berliner S, Fleischmann D, Aviram G. Increased mortality among patients with higher right ventricular volumes: Volumetric analysis of pre-transcatheter aortic valve replacement CT Angiography. EuroIntervention 2019; Jaa-660 2019. doi: 10.4244/EII-D-19-00651

Manuscript submission date: 15 July 2019

Revisions received: 27 August 2019

Accepted date: 27 September 2019

Online publication date: 01 October 2019

Disclaimer: This is a PDF file of a "Just accepted article". This PDF has been published online early without copy editing/typesetting as a service to the Journal's readership (having early access to this data). Copy editing/typesetting will commence shortly. Unforeseen errors may arise during the proofing process and as such Europa Digital & Publishing exercise their legal rights concerning these potential circumstances.

Increased mortality among patients with higher right ventricular volumes:

Volumetric analysis of pre-trans-catheter aortic valve replacement CT Angiography

Zach Rozenbaum, M.D.^a, Eva Maret M.D.^{b,c}, Lilian Lax, M.D.^d, Haim Shmilovich, M.D.^a, Ariel Finkelstein, M.D.^a, Arie Steinvil, M.D.^a, Amir Halkin, M.D.^a, Shmuel

Banai, M.D.^a, Dotan Cohen, M.D.^e, Yan Topilsky, M.D.^a, Shlomo Berliner, M.D., Ph.D. f, Dominik Fleischmann, M.D.^b, Galit Aviram, M.D.^d.

Brief Title: Automated RV volumetry and mortality in TAVR

^aDepartment of Cardiology, Tel Aviv Medical Affiliated to the Sackler School of Medicine, Tel Aviv University, Tel Aviv, Israel.

^bDepartment of Radiology, Stanford University School of Medicine, Stanford, California, U.S.A.

^cDepartment of Clinical Physiology, Karolinska University Hospital, and Karolinska Institutet, Stockholm Sweden.

^d Department of Radiology, Tel Aviv Medical Affiliated to the Sackler School of Medicine, Tel Aviv University, Tel Aviv, Israel.

^eDepartment of Cardiology, Hadassah Medical Center, Jerusalem, affiliated to the Hebrew University of Jerusalem, Jerusalem, Israel.

fInternal Medicine, Tel Aviv Medical Affiliated to the Sackler School of Medicine, Tel Aviv University, Tel Aviv, Israel.

Declarations of interest: Dr. Ariel Finkelstein receives proctor fees from Medtronic and Edwards life-sciences. Dr. Galit Aviram's institution receives a research grant from

Philips Health Care, unrelated to the present study. None of the other authors have disclosures to declare.

Corresponding author: Zach Rozenbaum, M.D. Department of Cardiology, Tel-Aviv Medical Center, 6 Weizman St, Tel-Aviv, 64239, Israel. Email: zachroze@gmail.com.

Abstract

Aims: To assess prognostic implications of increased right ventricle volume index (RVVI) using cardiac-gated computed tomography angiography (CCTA) data among patients undergoing trans-catheter valve implantation (TAVR).

Methods and Results: CCTA of 323 patients who underwent TAVR at Stanford University Medical Center (California, USA) and Tel Aviv Medical Center (Israel) between 2013-2016 were analyzed by an automatic 4-chamber volumetric software and grouped into quartiles according to their RVVI. Higher 1-year mortality rates were noted for the upper quartiles – 5%, 4.9%, 8.6%, and 16% (p=0.039), in Q1<59 ml/m², Q2 59-69 ml/m², Q3 69-86 ml/m², and Q4>83 ml/m², respectively. However, the differences were not significant after propensity score adjustments. Sub-analyses of Q1 demonstrated an escalating risk for 1-year mortality in concordance to RVVI; HR 2.28, HR 2.76, and HR 4.7, for the upper 25th, 15th, and 5th percentiles, respectively (p<0.05 for all comparisons). After propensity score adjustments for clinical and echocardiographic characteristics only the upper 5th percentiles (RVVI>120 ml/m²) retained statistical significance (HR 2.82, 95% CI 1.02-7.78, p=0.045). Notably, 68.7% of patients from this group were considered low-intermediate risk for surgery.

Conclusions: Cardiac volumetric data by CCTA performed for procedural planning may help predict outcome in patients undergoing TAVR.

Disclaimer: As a public service to our readership, this article -- peer reviewed by the Editors of EuroIntervention - has been published immediately upon acceptance as it was received. The content of this article is the sole responsibility of the authors, and not that of the journal

Keywords: Aortic stenosis; Imaging modalities; TAVI

Condensed abstract

CCTA of patients who underwent TAVR at Stanford University Medical Center

(California, USA) and Tel Aviv Medical Center (Israel) between 2013-2016 were

analyzed by an automatic 4-chamber volumetric software. After adjustment for

clinical and echocardiographic characteristics using a propensity score, patients with

large RV were at almost a 3-times higher risk for 1-year mortality despite having a

low STS score. Thus, cardiac volumetric data by CCTA performed for procedural

planning may help predict outcome in patients undergoing TAVR.

Abbreviations list

4CVA, automatic four cardiac chamber volumetric analysis

AS, aortic stenosis

CCTA, coronary computed tomography angiography

CI, confidence interval

HR, hazard ratio

IQR, interquartile range

LA, left atrium

LAVI, left atrial volume index

LV, left ventricle

RA, right atrium

RV, right ventricle

TAVR, trans-catheter aortic valve replacement

Introduction

Over the last decade, trans-catheter aortic valve replacement (TAVR) emerged as the treatment of choice in patients with severe aortic stenosis (AS) and prohibitive surgical risk [1,2,3,4,5]. Moreover, recent trials reported promising results even in low surgical risk patients [6,7]. However, clinical experience proves that some patients die relatively soon after the procedure [8]. Currently there are no validated methods for selection of suitable candidates. It had been suggested that patients with right heart failure as a late sequelae of left side valve disease are at an increased risk for adverse outcomes [9,10,11,12,13,14]. The assessment of right heart function is routinely performed by echocardiography, yet volumetric analysis by echocardiography, particularly right heart volumes, may not always be accurate [15,16,17,18]. Cardiac computed tomography angiography (CCTA) is the mandatory pre-interventional imaging modality for patients who are eligible for TAVR. The same imaging study may provide added information, such a cardiac volumetric assessment [19,20]. In the present study we used an automatic four cardiac chamber volumetric analysis (4CVA) of CCTA to calculate the RV size in patients undergoing CCTA prior to TAVR in two tertiary medical centers. We postulated that 4CVA of CCTA may contribute to risk stratification in pre-TAVR patients.

Methods

Study design and patient selection

Between January 2013 and March 2016 patients with severe symptomatic native AS (aortic valve area <1 cm²) who underwent TAVR at one of 2 medical centers - Stanford University Medical Center (California, USA) and Tel Aviv Sourasky Medical Center (TASMC), Israel - were included in the study. Clinical details were prospectively recorded for all patients at baseline and at a 1-year followup. Echocardiographic and CT data were recorded at baseline prior to the procedure. The study protocol was approved by the institutional review boards in both centers. Requirement for informed consent was waived due to the retrospective nature of the nterver study.

CCTA acquisition

Retrospectively - gated CCTA were performed with a second-generation dualsource CT (Siemens SOMATOM Definition Flash) at Stanford University Medical Center (n=152) or with a 256x0.625 mm detector rows scanner (iCT 256 Philips Health Care) in TASMC (n=171). At Stanford University Medical Center Cardiac gated chest scan began in the thoracic outlet, and ended at the diaphragm, followed by non-gated abdominal scan which were acquired with contrast injections of 60-110 mL (1.2 mL/kg) of iodinated contrast material at a concentration of 300 mg iodine per mL (Iopamidole, Bracco, Princeton, NJ) at an injection rate of 4-5 mL/sec. In TASMC, scans were acquired with contrast injections of 40-70 mL (0.8 mL/kg) of iodinated contrast material at a concentration of 300 mg iodine per mL (Iomeron, Bracco, Milano, Italy) at an injection rate of 4-5 mL/sec. CT scanning was initiated using automated bolus triggering five seconds after the attenuation in the ascending aorta reached a threshold of 100 Hounsfield Units covering the heart from the tracheal

Disclaimer: As a public service to our readership, this article -- peer reviewed by the Editors of EuroIntervention - has been published immediately upon acceptance as it was received. The content of this article is the sole responsibility of the authors, and not that of the journal

bifurcation to the diaphragm . When abdominal aortic scan was included in the same acquisition, the scan began at the tracheal bifurcation and ended at the femoral arterial bifurcation level, and the injected volume was 60-110 mL (1.2 mL/kg). Data were reconstructed at slice thickness of 0.8 mm or 0.75mm, with an increment of 0.4 mm. Measurements of the aortic annulus were done during the systolic phase scan (35% or 40% of the R to R interval), while all automated volumetric analysis assessments were done on a mid-diastolic phase scan (75% of the R to R interval) which is considered the phase with least motion artifacts [20]. When significant variability in the heart rate was observed, ECG editing was performed immediately following the scan acquisition, and the images used for the annular measurements (at the systolic phase), and the volumetric assessment (at mid-diastolic phase - 75% of the new edited R to R interval), were used.

Volumetric analysis of the cardiac chambers

Automated volumetric measurements of the RV, right atrium (RA), left ventricle (LV), and the left atrium (LA), were obtained using a fully automatic software (Comprehensive Cardiac Analysis, IntelliSpace, Portal Version 6; Philips Healthcare, Cleveland, OH). The algorithm adapts an anatomical model of the heart chambers to the CT image volume [20,21,22]. The output of the volumetric analysis consisted of a three-dimensional (3D) graphic display of the heart segmented into its main structures. We analyzed the volumes of the RV, RA, LV and LA. The volume of each cardiac chamber was automatically calculated as the product of a single voxel volume and the sum of all voxels were included in it. The software allows the relevant segmentation structure to be color-coded and viewed simultaneously in both 3D and 2D superimposed on the reference image in the axial, coronal, sagittal, or cardiac

views (short axis, vertical long axis, horizontal long axis). Each structure was inspected visually on the reference images for conformity to the imaged cardiac anatomy in order to validate the correctness of the segmentation. In cases where the automatic segmentation was visually assessed as incorrect, the chamber's volumetric data were excluded from the study (42 out of 365 patients). Manual tools for correction of the volumetric segmentation are available but were not used in the present study. Volumes were indexed to body surface area and reported as volume indices (ml/m²). Figure 1 shows an example of the automated segmentation output of ntion a patient with an enlarged RV who died within 1-year.

Statistical analysis

Categorical variables were expressed as percentages. Distribution of continuous variables was assessed using histogram and Q-Q plot and expressed as median and interquartile range (IQR). A cubic non-linear regression was used to present the relation between RV volume indices and 1-year mortality. Each volume was correlated to the corresponding average of observed events (i.e. percentages of 1year mortality) on the y-axis. The trend line was formed according to the eventual estimated non-linear cubic relation. The reference line was set by the overall mean mortality. RV volume indices were divided into quartiles and compared to the lower quartile in regard with mortality risk. Cox regressions were used to assess the relation between RV size and 1-year mortality. Hazard ratios (HRs) and 95% confidence intervals (CIs) were reported. A sub-analysis of the higher quartile was then performed to evaluate cut-offs at which RV volume is independently associated with 1-year mortality. Propensity scores were used to adjust for baseline characteristics (age, gender, body mass index, hypertension, diabetes mellitus, hyperlipidemia,

peripheral vascular disease, coronary artery disease, prior myocardial infarction, prior coronary artery bypass graft, prior valve surgery, permanent pacemaker, atrial fibrillation, CVA/TIA, renal dysfunction, dialysis, COPD, NYHA class IV, STS score), the medical center at which the TAVR was performed, and echocardiographic parameters (interventricular septum, left ventricle ejection fraction, aortic valve area index, aortic valve gradients, left atrial volume index, E/e, E/A, systolic pulmonary artery pressure, mitral regurgitation). A two-tailed p<0.05 was considered statistically significant. All statistical analyses were performed with SPSS (IBM Corp. Released 2013. IBM SPSS Statistics for Windows, Version 22.0. Armonk, NY: IBM Corp.). Nentio

Results

Baseline characteristics

The cohort consisted of 323 patients, 152 from Stanford University School of Medicine and 171 from Tel Aviv Medical Center. The median age was 84 (IQR 80-88) years, the median STS score was 4.8% (IQR 3-7.4), and 51.4% were of female gender. Baseline characteristics according to a division into quartiles of RV volumes (Q1 <59 ml/m², Q2 59-69 ml/m², 69-86 ml/m², Q4 >83 ml/m²) are presented in Table 1. Patients within the upper quartiles demonstrated lower BMIs, increased rates of female gender and higher STS scores. A higher prevalence of ischemic heart disease (coronary artery disease and prior coronary artery bypass graft) and atrial fibrillation were noted in the upper quartiles of RV volumes. The remaining co-morbidities, as well as the NYHA class, did not statistically differ across the groups. A lowintermediate (STS<8%) pre-procedural surgical risk was estimated in 86.2%, 87.7%, 80.2%, and 70.3% of patients within Q1, Q2, Q3, Q4, respectively (supplemental Table 1).

CT and echocardiography

Baseline imaging parameters according to RV volume are presented in Table 2. Echocardiography was available for 273 patients. Patients within the upper quartiles presented with larger volumes of all cardiac chambers by CT. Echocardiography demonstrated reduced systolic and diastolic function in the upper quartile of RV volumes, according to LV ejection fraction, E/A ratio, LA volume index, and systolic pulmonary artery pressure. Aortic valve area indices were lower and aortic valve gradients (peak and mean) were higher in the upper quartiles of RV volumes. In addition, mitral regurgitation of moderate degree or above was more prevalent in the upper quartile of RV volumes.

At 1-year, 28 patients (8.7%) from the entire cohort were deceased. There were no significant differences in 30-day mortality between the groups – 2.5%, 2.5%, 3.7%, 3.7% (p>0.999) in Q1, Q2, Q3, Q4, respectively. The relation between right ventricle volume indices and 1-year mortality is presented in Figure 2. At 1-year a significantly increased mortality rate was noted for the upper quartiles – 5%, 4.9%, 8.6%, 16% (p=0.039), in Q1, Q2, Q3, Q4, respectively. In a univariable analysis (Figure 3) the upper quartile of RV volumes was associated with increased mortality compared to the lower quartile (HR 3.74, 95% CI 1.04-13.40, p=0.043). Adjustments for baseline characteristics with propensity scores eliminated the differences (p>0.5; Table 3). Sub-analyses of Q1 - upper 25th percentiles (>83 ml/m²; n=81) vs lower 75th percentiles, upper (>96 ml/m²; n=48) 15th percentiles vs lower 85th percentiles, and upper (>120 ml/m²; n=16) 5th percentiles vs lower 95th percentiles – demonstrated escalating hazard ratios for 1-year mortality in concordance to RV volumes; HR 2.28 (95% CI 1.10-4.75, p=0.027), HR 2.76 (95% CI 1.25-6.09, p=0.012), and HR 4.7 (95% CI 1.80-12.4, p=0.002), respectively. However, after

Disclaimer: As a public service to our readership, this article -- peer reviewed by the Editors of EuroIntervention - has been published immediately upon acceptance as it was received. The content of this article is the sole responsibility of the authors, and not that of the journal

adjustments for clinical and echocardiographic characteristics (listed in Table 4) with propensity scores, only the upper 5th percentiles of RV volumes retained statistical significance (HR 2.82, 95% CI 1.02-7.78, p=0.045).

Discussion

This is a two-center retrospective analysis of patients undergoing TAVR due to severe AS. The principal finding is that larger RV volume which was automatically calculated based on volumetric analysis of CCTA, is associated with higher mortality at 1-year following the procedure, thus may contribute to risk stratification and predict outcome of patients undergoing TAVR. Notably, approximately 70% of patients with large RV were considered low-intermediate risk for surgery.

Our results are in line with the current literature, showing that patients with RV enlargement who undergo left sided valve interventions have poor outcomes [23], and reduced 1-year survival rates [12]. Right chamber dilatation may occur in patients with AS because of pressure overload from increased left-sided filling pressures and pulmonary artery pressures transmitted to the right side, volume overload from fluid retention or concomitant tricuspid regurgitation, or ventricular interdependence [23,24]. Therefore, it is not surprising that RV dysfunction is a not an uncommon finding, and is associated with adverse outcomes [9,10,11,12,13,14]. As expected, in the present cohort patients with dilated RV had increased pulmonary artery pressure. However, even after adjustment for systolic pulmonary artery pressure (estimated by echocardiography), as well as left side filling pressures and ejection fraction, dilated RV by CT remained an independent predictor of outcome. Thus, in patients with severe RV dilatation the insult of the left-to-right hemodynamic cascade might signify irreversibility, and RV recovery does not consistently ensue after TAVR.

A conspicuous difference between the groups which should be addressed is the distribution of gender across the groups. It is postulated that females carry a better prognosis following TAVR [25]. Nevertheless, gender disparities were adjusted for in the propensity scores. Likewise, the potential anatomical inequalities were accounted for, by providing volume indices (volume per body surface area).

Previous studies had almost been exclusively based on echocardiography. Right heart volume quantification by echocardiography is known to be limited due to the chamber's complex anatomy [14,15,16,17,18]. Currently, there is no precise geometric model which accounts for the volumetric assumptions of the RV, particularly among patients with fluid overload [16]. Measurements may differ significantly at various distances between the tricuspid annulus and the apex [17,26]. It is consequently recommended that the right heart should be imaged from multiple acoustic windows, and therefore the report is depended on a subjective interpretation of the acquired images by the echocardiographer. Moreover, while in certain instances it may be difficult to detect mild abnormalities in RV size [17], it was shown that volumes tend to be overestimated at certain ranges but underestimated in others [15].

We chose to use the fully automated algorithm of the 4CVA for RV volume determination while refraining from corrections with manual tools, in order to emphasize its advantages of easy and fast provision of highly valuable information. This software was trained to identify the various cardiac compartments based on a pre-learned anatomical model, thus enabling efficient workflow by automated cardiac chamber volume calculation. The output of the automated calculations was compared with the results from intensive labor manual segmentation and found to be accurate and highly reproducible [20]. By all means, most post-processing platforms do offer

tools which allow assessment of the RV volumes manually or with semi-automated

Disclaimer: As a public service to our readership, this article -- peer reviewed by the Editors of EuroIntervention - has been published immediately upon acceptance as it was received. The content of this article is the sole responsibility of the authors,

and not that of the journal

tools. However, developing strategies that can reliably transform complex visual observations into well-defined algorithmic procedures is an active area of exploration that can enhance clinical practice. Other studies have shown that objectivity, reproducibility, and sensitivity are often improved when characterizations are based upon computer-aided analyses [27].

Limitations

There are several limitations that must be taken into consideration. First, the study is retrospective. Such a design may introduce inherent biases. Second, the high-risk population, i.e. the upper 5th percentile of RV volume, consisted of merely 16 patients, thereby limiting the power of the analysis. Third, volumes were measured at 75% of diastole due to the lowest presence of motion artifacts, therefore they do not represent end-diastole. In a tradeoff between minimizing inaccuracies of the segmentation and determining the true end-diastole volumes, the former prevailed. Furthermore, these methods were consistent for all patients and previous studies examined a similar approach [20,28]. Thin slice-end-diastolic images were not available for our retrospective analysis. Finally, since estimation of RV size with echocardiography is limited in certain cases, such data were not collected and therefore a volumetric comparison for validation purposes was not performed.

Conclusions

In the current study we used objective, non-operator dependent CT data, which were freely available from the already acquired pre-procedural CCTA. Our findings demonstrate that RV enlargement is associated with increased 1-year morality among patients with severe AS undergoing TAVR, regardless of the pre-procedural surgical risk. We thus believe that utilizing data from the CCTA which is

used for procedural planning, can be beneficial and contribute to clinical decision making and setting expectations with patients and their families.

Impact on daily practice

The presented data demonstrates that cardiac volumetric data by CCTA performed for procedural planning may help predict outcome in patients undergoing TAVR and identify patients who are at high risk for adverse outcomes despite having a low preprocedural surgical risk.

Funding: None

References

- Gilard M, Eltchaninoff H, Iung B, Donzeau-Gouge P, Chevreul K, Fajadet J, Leprince P, Leguerrier A, Lievre M, Prat A, Teiger E, Lefevre T, Himbert D, Tchetche D, Carrié D, Albat B, Cribier A, Rioufol G, Sudre A, Blanchard D, Collet F, Dos Santos P, Meneveau N, Tirouvanziam A, Caussin C, Guyon P, Boschat J, Le Breton H, Collart F, Houel R, Delpine S, Souteyrand G, Favereau X, Ohlmann P, Doisy V, Grollier G, Gommeaux A, Claudel JP, Bourlon F, Bertrand B, Van Belle E, Laskar M; FRANCE 2 Investigators. Registry of transcatheter aortic-valve implantation in high-risk patients. N Engl J Med 2012;366:1705-15
- 2. Kodali SK, Williams MR, Smith CR, Svensson LG, Webb JG, Makkar RR, Fontana GP, Dewey TM, Thourani VH, Pichard AD, Fischbein M, Szeto WY, Lim S, Greason KL, Teirstein PS, Malaisrie SC, Douglas PS, Hahn RT, Whisenant B, Zajarias A, Wang D, Akin JJ, Anderson WN, Leon MB; PARTNER Trial Investigators. Two-year outcomes after

- transcatheter or surgical aortic-valve replacement. N Engl J Med 2012;366:1686-95
- 3. Leon MB, Smith CR, Mack MJ, Makkar RR, Svensson LG, Kodali SK, Thourani VH, Tuzcu EM, Miller DC, Herrmann HC, Doshi D, Cohen DJ, Pichard AD, Kapadia S, Dewey T, Babaliaros V, Szeto WY, Williams MR, Kereiakes D, Zajarias A, Greason KL, Whisenant BK, Hodson RW, Moses JW, Trento A, Brown DL, Fearon WF, Pibarot P, Hahn RT, Jaber WA, Anderson WN, Alu MC, Webb JG. Transcatheter or Surgical Aortic-Valve Replacement in Intermediate-Risk Patients. N Engl J Med 2016;374:1609-20
- 4. Makkar RR, Fontana GP, Jilaihawi H, Kapadia S, Pichard AD, Douglas PS, Thourani VH, Babaliaros VC, Webb JG, Herrmann HC, Bavaria JE, Kodali S, Brown DL, Bowers B, Dewey TM, Svensson LG, Tuzcu M, Moses JW, Williams MR, Siegel RJ, Akin JJ, Anderson WN, Pocock S, Smith CR, Leon MB. Transcatheter aortic-valve replacement for inoperable severe aortic stenosis. N Engl J Med 2012;366:1696-70.
- 5. Wenaweser P, Stortecky S, Schwander S, Heg D, Huber C, Pilgrim T, Gloekler S, O'Sullivan CJ, Meier B, Jüni P, Carrel T, Windecker S. Clinical outcomes of patients with estimated low or intermediate surgical risk undergoing transcatheter aortic valve implantation. Eur Heart J 2013;34:1894-905
- Popma JJ, Deeb GM, Yakubov SJ, Mumtaz M, Gada H, O'Hair D, Bajwa T, Heiser JC, Merhi W, Kleiman NS, Askew J, Sorajja P, Rovin J, Chetcuti SJ, Adams DH, Teirstein PS, Zorn GL 3rd, Forrest JK, Tchétché
- D, Resar J, Walton A, Piazza N, Ramlawi B, Robinson N, Petrossian G,

 Disclaimer: As a public service to our readership, this article -- peer reviewed by the Editors of EuroIntervention has been published immediately upon acceptance as it was received. The content of this article is the sole responsibility of the authors, and not that of the journal

- Gleason TG, Oh JK, Boulware MJ, Qiao H, Mugglin AS, Reardon MJ;
 Evolut Low Risk Trial Investigators. Transcatheter Aortic-Valve
 Replacement with a Self-Expanding Valve in Low-Risk Patients. N Engl J
 Med 2019;380:1706-1715
- 7. Mack MJ, Leon MB, Thourani VH, Makkar R, Kodali SK, Russo M, Kapadia SR, Malaisrie SC, Cohen DJ, Pibarot P, Leipsic J, Hahn RT, Blanke P, Williams MR, McCabe JM, Brown DL, Babaliaros V, Goldman S, Szeto WY, Genereux P, Pershad A, Pocock SJ, Alu MC, Webb JG, Smith CR; PARTNER 3 Investigators. Transcatheter Aortic-Valve Replacement with a Balloon-Expandable Valve in Low-Risk Patients. N Engl J Med 2019;380:1695-1705
- 8. Arnold SV, Reynolds MR, Lei Y, Magnuson EA, Kirtane AJ, Kodali SK, Zajarias A, Thourani VH, Green P, Rodés-Cabau J, Beohar N, Mack MJ, Leon MB, Cohen DJ; PARTNER Investigators. Predictors of poor outcomes after transcatheter aortic valve replacement: results from the PARTNER (Placement of Aortic Transcatheter Valve) trial. Circulation 2014;129:2682-90
- Schwartz LA, Rozenbaum Z, Ghantous E, Kramarz J, Biner S, Ghermezi M, Shimiaie J, Finkelstein A, Banai S, Aviram G, Ingbir M, Keren G, Topilsky Y. Impact of Right Ventricular Dysfunction and Tricuspid Regurgitation on Outcomes in Patients Undergoing Transcatheter Aortic Valve Replacement. J Am Soc Echocardiogr 2017;30:36-46
- 10. Asami M, Stortecky S, Praz F, Lanz J, Räber L, Franzone A, Piccolo R, Siontis GCM, Heg D, Valgimigli M, Wenaweser P, Roost E, Windecker S,

Pilgrim T. Prognostic Value of Right Ventricular Dysfunction on Clinical Disclaimer: As a public service to our readership, this article -- peer reviewed by the Editors of EuroIntervention - has been published immediately upon acceptance as it was received. The content of this article is the sole responsibility of the authors, and not that of the journal

- Outcomes After Transcatheter Aortic Valve Replacement. JACC Cardiovasc Imaging 2019;12:577-587
- 11. Ren B, Spitzer E, Geleijnse ML, Zijlstra F, de Jaegere PPT, Van Mieghem NM, Tijssen JG. Right ventricular systolic function in patients undergoing transcatheter aortic valve implantation: A systematic review and meta-analysis. Int J Cardiol 2018;257:40-45
- 12. Lindman BR, Maniar, HS, Jaber WA, Lerakis, S, Mack MJ, Suri RM, Thourani VH, Babaliaros V, Kereiakes DJ, Whisenant B, Miller DC, Tuzcu EM, Svensson LG, Xu K, Doshi D, Leon MB, Zajarias A. Effect of tricuspid regurgitation and the right heart on survival after transcatheter aortic valve replacement: insights from the Placement of Aortic Transcatheter Valves II inoperable cohort. Circ Cardiovasc Interv 2015;8:e002073
- 13. Ito S, Pislaru SV, Soo WM, Huang R, Greason KL, Mathew V, Sandhu GS, Eleid MF, Suri RM, Oh JK, Nkomo VT. Impact of right ventricular size and function on survival following transcatheter aortic valve replacement. Int J Cardiol 2016;221:269-74
- 14. Lindqvist P, Calcutteea A, Henein M. Echocardiography in the assessment of right heart function. Eur J Echocardiogr 2008;9:225-34
- 15. Rozenbaum Z, Granot Y, Steinvil A, Banai S, Finkelstein A, Ben-Gal Y, Keren G, Topilsky Y. Aortic Stenosis with Severe Tricuspid Regurgitation: Comparative Study between Conservative Transcatheter Aortic Valve Replacement and Surgical Aortic Valve Replacement Combined With Tricuspid Repair. J Am Soc Echocardiogr 2018;31:1101-

- 16. Shimada YJ, Shiota M, Siegel RJ, Shiota T. Accuracy of right ventricular volumes and function determined by three-dimensional echocardiography in comparison with magnetic resonance imaging: a meta-analysis study. J Am Soc Echocardiogr 2010;23:943-53
- 17. Lai WW, Gauvreau K, Rivera ES, Saleeb S, Powell AJ, Geva T. Accuracy of guideline recommendations for two-dimensional quantification of the right ventricle by echocardiography. Int J Cardiovasc Imaging 2008;24:691–8
- 18. Schneider M, Thomas Binder T. Echocardiographic evaluation of the right heart. Wien Klin Wochenschr 2018;130:413–420
- 19. Salgado RA, Leipsic JA, Shivalkar B, Ardies L, Van Herck PL, Op de Beeck BJ, Vrints C, Rodrigus I, Parizel PM, Bosmans J. Preprocedural CT Evaluation of Transcatheter Aortic Valve Replacement: What the Radiologist Needs to Know. Radiographics 2014;34:1491-514
- 20. Mao SS, Li D, Vembar M, Gao Y, Luo Y, Lam F, Syed YS, Liu C, Woo K, Flores F, Budoff MJ. Model-based automatic segmentation algorithm accurately assesses the whole cardiac volumetric parameters in patients with cardiac CT angiography: a validation study for evaluating the accuracy of the workstation software and establishing the reference values. Acad Radiol 2014;21:639-47
- 21. Abadi S, Roguin A, Engel A, Lessick J. Feasibility of automatic assessment of four chamber cardiac function with MDCT: Initial clinical application and validation. Eur J Radiol 2010;74:175–181
- 22. Ecabert O, Peters J, Schramm H, Lorenz C, von Berg J, Walker MJ,

- model-based segmentation of the heart in CT images. IEEE Trans Med Imaging 2008;27:1189-1201
- 23. Nagel E, Stuber M, Hess OM. Importance of the right ventricle in valvular heart disease. Eur Heart J 1996 Jun;17:829-36
- 24. Grose R, Strain J, Yipintosoi T. Right ventricular function in valvular heart disease: relation to pulmonary artery pressure. J Am Coll Cardiol 1983;2:225-32
- 25. Chandrasekhar J, Dangas G, Yu J, Vemulapalli S, Suchindran S, Vora AN, Baber U, Mehran R; STS/ACC TVT Registry. Sex-Based Differences in Outcomes With Transcatheter Aortic Valve Therapy: TVT Registry From 2011 to 2014. J Am Coll Cardiol 2016;68:2733-2744
- 26. Rudski LG, Lai WW, Afilalo J, Hua L, Handschumacher MD, Chandrasekaran K, Solomon SD, Louie EK, Schiller NB.. Echocardiographic Assessment of the Right Heart in Adults: A Report from the American Society of Echocardiography Endorsed by the European Association of Echocardiography and the Canadian Society of Echocardiography. JASE 2010;23:685-713
- 27. Foran DJ, Chen W and Yang L. Automated image interpretation and computer-assisted diagnostics. Stud Health Technol Inform 2013;185:77-108
- 28. Walker JR, Abadi S, Solomonica A, Mutlak D, Aronson D, Agmon Y, Lessick J. Left-sided cardiac chamber evaluation using single-phase middiastolic coronary computed tomography angiography: derivation of normal values and comparison with conventional end-diastolic and endsystolic phases. Eur Radiol 2016;26:3626–3634

Figures legends

Figure 1: Output example of the fully automated 4-chamber volumetric analysis of the pre-TAVR cardiac CT angiography showing an enlarged right ventricle (right ventricular volume index=127.4 mL/m²).

A. Volumetric model of the 4-cardiac chambers. B. Vertical long axis reformation (4-chamber view). C. Oblique (3-chamber view). Arrow showing the calcified aortic valve. Color code: left atrium = purple, left ventricle = pink, right atrium = yellow, and right ventricle = orange. Abbreviations: LA, left atrium; LV, left ventricle; RA, right atrium; RV, right ventricle.

Figure 2: Relation between right ventricle volume indices and 1-year mortality

Figure 3: Cox survival curves according to right ventricle volume index

Table 1: Baseline characteristics according to right ventricle volume

Q1						
ml/m² ml/m		Q1				p-
N=80		(<59	(59-69	(69-86	(>86	value
Age (years) 82(79-88) 85(81-88) 84(79-87) 85(80-89) 0.560 Female gender (%) 74 49 56 27 <0.001		ml/m^2)	ml/m^2)	ml/m^2)	ml/m^2)	
Age (years) 82(79-88) 85(81-88) 84(79-87) 85(80-89) 0.560 Female gender (%) 74 49 56 27 <0.001		ŕ	ŕ	ŕ		
Age (years) 82(79-88) 85(81-88) 84(79-87) 85(80-89) 0.560 Female gender (%) 74 49 56 27 <0.001		n=80	n=81	n=81	n=81	
Female gender (%) 74 49 56 27 <0.001 BMI (kg/m²) 27.6(24.4-230.8) 26.8(23.2-30.7) 28.2) 0.033 Hypertension (%) 85 79 84 89 0.404 Diabetes mellitus (%) 42 28 25 39 0.054 Dyslipidaemia (%) 82 76 75 79 0.680 Coronary artery disease (%) 46 54 64 69 0.020 Prior myocardial infarction (%) 14 17 25 27 0.114 Prior coronary artery bypass graft (%) 7 17 18 27 0.012 Prior valve surgery (%) 1 3 1 5 0.469 Permanent pacemaker (%) 5 9 5 11 0.364 Atrial fibrillation (%) 15 32 41 43 <0.001	Age (years)					0.560
Female gender (%) 74 49 56 27 <0.001 BMI (kg/m²) 27.6(24.4-30.8) 26.4(23-30.8) 25.1(23-20.0033) 0.003 Hypertension (%) 85 79 84 89 0.404 Diabetes mellitus (%) 42 28 25 39 0.054 Dyslipidaemia (%) 82 76 75 79 0.680 Coronary artery disease (%) 46 54 64 69 0.020 Prior myocardial infarction (%) 14 17 25 27 0.114 Prior coronary artery bypass graft (%) 7 17 18 27 0.012 Permanent pacemaker (%) 1 3 1 5 0.469 Permanent pacemaker (%) 5 9 5 11 0.364 Peripheral vascular disease (%) 15 32 41 43 <0.001	rige (years)	02(17 00)	03(01 00)	01(75 07)	,	0.500
BMI (kg/m²) 27.6(24.4-30.8) 30.1) 30.7) 28.2) Hypertension (%) 85 79 84 89 0.404 Diabetes mellitus (%) 42 28 25 39 0.054 Dyslipidaemia (%) 82 76 75 79 0.680 Coronary artery 46 54 64 69 0.020 (114 infarction (%) 70 114 infarction (%) 70 114 infarction (%) 70 114 infarction (%) 70 115 11 11 11 11 11 11 11 11 11 11 11 11	Famala gandar (9/)	7.1	40	56		<0.001
Hypertension (%) 85 79 84 89 0.404 Diabetes mellitus (%) 42 28 25 39 0.054 Dyslipidaemia (%) 82 76 75 79 0.680 Coronary artery disease (%) 46 54 64 69 0.020 Prior myocardial infarction (%) 14 17 25 27 0.114 Prior coronary artery bypass graft (%) 1 3 1 5 0.469 Permanent pacemaker (%) 15 32 41 43 <0.001 Peripheral vascular disease (%) 15 32 41 43 <0.001 Peripheral vascular disease (%) 12 16 20 26 0.140 Renal dysfunction (%) 15 37 31 36 0.285 NYHA class IV (%) 15 17 20 20 0.842 STS score (%) 4.1(2.7- 4.2(2.8- 4.5(2.7- 6.2(4.1- <0.001	remaie gender (%)	/4	49	30	2.7	\0.001
Hypertension (%) 85 79 84 89 0.404 Diabetes mellitus (%) 42 28 25 39 0.054 Dyslipidaemia (%) 82 76 75 79 0.680 Coronary artery disease (%) 46 54 64 69 0.020 Prior myocardial infarction (%) 14 17 25 27 0.114 Prior coronary artery bypass graft (%) 1 3 1 5 0.469 Permanent pacemaker (%) 15 32 41 43 <0.001 Peripheral vascular disease (%) 15 32 41 43 <0.001 Peripheral vascular disease (%) 12 16 20 26 0.140 Renal dysfunction (%) 15 37 31 36 0.285 NYHA class IV (%) 15 17 20 20 0.842 STS score (%) 4.1(2.7- 4.2(2.8- 4.5(2.7- 6.2(4.1- <0.001	$PMI(l_{rg}/m^2)$	27.6(24.4	26.4(23	26.8(23.2	25 1(23	0.033
Hypertension (%)	Divii (kg/iii)	,	`	`	`	0.055
Diabetes mellitus (%)	11 (0/)	,				0.404
Dyslipidaemia (%) 82 76 75 79 0.680	Hypertension (%)	85	7/9	84	89	0.404
Dyslipidaemia (%) 82 76 75 79 0.680	Diahatas mallitus (9/)	12	20	25	20	0.054
Coronary artery disease (%) 46 54 64 69 0.020 Prior myocardial infarction (%) 14 17 25 27 0.114 Prior coronary artery bypass graft (%) 7 17 18 27 0.012 Permanent pacemaker (%) 1 3 1 5 0.469 Permanent pacemaker (%) 5 9 5 11 0.364 Atrial fibrillation (%) 15 32 41 43 <0.001	Diabetes memus (%)	42	20	23	39	0.034
Coronary artery disease (%) 46 54 64 69 0.020 Prior myocardial infarction (%) 14 17 25 27 0.114 Prior coronary artery bypass graft (%) 7 17 18 27 0.012 Permanent pacemaker (%) 1 3 1 5 0.469 Permanent pacemaker (%) 5 9 5 11 0.364 Atrial fibrillation (%) 15 32 41 43 <0.001	Dyslipidaemia (%)	82	76	75	79	0.680
disease (%) 14 17 25 27 0.114 Prior myocardial infarction (%) 14 17 25 27 0.114 Prior coronary artery bypass graft (%) 7 17 18 27 0.012 Prior valve surgery (%) 1 3 1 5 0.469 Permanent pacemaker (%) 5 9 5 11 0.364 Atrial fibrillation (%) 15 32 41 43 <0.001					-	
Prior myocardial infarction (%) 14 17 25 27 0.114 Prior coronary artery bypass graft (%) 7 17 18 27 0.012 Prior valve surgery (%) 1 3 1 5 0.469 Permanent pacemaker (%) 5 9 5 11 0.364 Atrial fibrillation (%) 15 32 41 43 <0.001	Coronary artery	46	54	64	69	0.020
infarction (%) 7 17 18 27 0.012 Prior coronary artery bypass graft (%) 7 17 18 27 0.012 Prior valve surgery (%) 1 3 1 5 0.469 Permanent pacemaker (%) 5 9 5 11 0.364 Atrial fibrillation (%) 15 32 41 43 <0.001	disease (%)				- (01)	
infarction (%) 7 17 18 27 0.012 Prior coronary artery bypass graft (%) 7 17 18 27 0.012 Prior valve surgery (%) 1 3 1 5 0.469 Permanent pacemaker (%) 5 9 5 11 0.364 Atrial fibrillation (%) 15 32 41 43 <0.001	Prior myocardial	14	17	25	27	0.114
Prior coronary artery bypass graft (%) 7 17 18 27 0.012 Prior valve surgery (%) 1 3 1 5 0.469 Permanent pacemaker (%) 5 9 5 11 0.364 Atrial fibrillation (%) 15 32 41 43 <0.001			-			
bypass graft (%) 1 3 1 5 0.469 Permanent pacemaker (%) 5 9 5 11 0.364 Atrial fibrillation (%) 15 32 41 43 <0.001		7	17	18	27	0.012
Prior valve surgery (%) 1 3 1 5 0.469 Permanent pacemaker (%) 5 9 5 11 0.364 Atrial fibrillation (%) 15 32 41 43 <0.001	_	,	1/	10	21	0.012
Permanent pacemaker (%) Atrial fibrillation (%) Peripheral vascular disease (%) CVA/TIA (%) Renal dysfunction (%) Dialysis (%) COPD (%) 22 11 14 16 0.364 0.364 0.364 10 15 22 16 0.145 10 0.145 10 0.145 10 0.145 10 0.145 11 0.364 0.364		1	2	1	5	0.460
Atrial fibrillation (%) 15 32 41 43 <0.001 Peripheral vascular disease (%) 10 15 23 16 0.145 CVA/TIA (%) 12 16 20 26 0.140 Renal dysfunction (%) 56 57 51 56 0.841 Dialysis (%) 1 0 0 0 0.490 COPD (%) 22 11 14 16 0.285 NYHA class IV (%) 15 17 20 20 0.842 STS score (%) 4.1(2.7- 4.2(2.8- 4.5(2.7- 6.2(4.1- <0.001	Prior valve surgery (%)	1	0.0	1	3	0.469
Atrial fibrillation (%) 15 32 41 43 <0.001 Peripheral vascular disease (%) 10 15 23 16 0.145 CVA/TIA (%) 12 16 20 26 0.140 Renal dysfunction (%) 56 57 51 56 0.841 Dialysis (%) 1 0 0 0 0.490 COPD (%) 22 11 14 16 0.285 NYHA class IV (%) 15 17 20 20 0.842 STS score (%) 4.1(2.7- 4.2(2.8- 4.5(2.7- 6.2(4.1- <0.001	Permanent pacemaker	5	9	5	11	0.364
Atrial fibrillation (%) 15 32 41 43 <0.001	<u>-</u>					
Peripheral vascular disease (%) 10 15 23 16 0.145 CVA/TIA (%) 12 16 20 26 0.140 Renal dysfunction (%) 56 57 51 56 0.841 Dialysis (%) 1 0 0 0 0.490 COPD (%) 22 11 14 16 0.285 NYHA class IV (%) 15 17 20 20 0.842 STS score (%) 4.1(2.7- 4.2(2.8- 4.5(2.7- 6.2(4.1- <0.001		15	22	// 1	12	<0.001
disease (%) disease (%) 12 16 20 26 0.140 Renal dysfunction (%) 56 57 51 56 0.841 Dialysis (%) 1 0 0 0 0.490 COPD (%) 22 11 14 16 0.285 NYHA class IV (%) 15 17 20 20 0.842 STS score (%) 4.1(2.7- 4.2(2.8- 4.5(2.7- 6.2(4.1- <0.001	Attial Hormation (70)	13	32	41	43	\0.001
disease (%) 12 16 20 26 0.140 Renal dysfunction (%) 56 57 51 56 0.841 Dialysis (%) 1 0 0 0 0.490 COPD (%) 22 11 14 16 0.285 NYHA class IV (%) 15 17 20 20 0.842 STS score (%) 4.1(2.7- 4.2(2.8- 4.5(2.7- 6.2(4.1- <0.001	Peripheral vascular	10	15	23	16	0.145
CVA/TIA (%) 12 16 20 26 0.140 Renal dysfunction (%) 56 57 51 56 0.841 Dialysis (%) 1 0 0 0 0.490 COPD (%) 22 11 14 16 0.285 NYHA class IV (%) 15 17 20 20 0.842 STS score (%) 4.1(2.7- 4.2(2.8- 4.5(2.7- 6.2(4.1- <0.001						
Renal dysfunction (%) 56 57 51 56 0.841 Dialysis (%) 1 0 0 0 0.490 COPD (%) 22 11 14 16 0.285 NYHA class IV (%) 15 17 20 20 0.842 STS score (%) 4.1(2.7- 4.2(2.8- 4.5(2.7- 6.2(4.1- <0.001		12	16	20	26	0.140
Dialysis (%) 1 0 0 0 0.490 COPD (%) 22 11 14 16 0.285 NYHA class IV (%) 15 17 20 20 0.842 STS score (%) 4.1(2.7- 4.2(2.8- 4.5(2.7- 6.2(4.1- <0.001	CVIVIII (70)	12	10	20	20	0.140
Dialysis (%) 1 0 0 0 0.490 COPD (%) 22 11 14 16 0.285 NYHA class IV (%) 15 17 20 20 0.842 STS score (%) 4.1(2.7- 4.2(2.8- 4.5(2.7- 6.2(4.1- <0.001	Renal dysfunction (%)	56	57	51	56	0.841
COPD (%) 22 11 14 16 0.285 NYHA class IV (%) 15 17 20 20 0.842 STS score (%) 4.1(2.7- 4.2(2.8- 4.5(2.7- 6.2(4.1- <0.001						
COPD (%) 22 11 14 16 0.285 NYHA class IV (%) 15 17 20 20 0.842 STS score (%) 4.1(2.7- 4.2(2.8- 4.5(2.7- 6.2(4.1- <0.001	Dialysis (%)	1	0	0	0	0.490
NYHA class IV (%) 15 17 20 20 0.842 STS score (%) 4.1(2.7- 4.2(2.8- 4.5(2.7- 6.2(4.1- <0.001		-	Ü	Ŭ	· ·	0.150
NYHA class IV (%) 15 17 20 20 0.842 STS score (%) 4.1(2.7- 4.2(2.8- 4.5(2.7- 6.2(4.1- <0.001	COPD (%)	22	11	1.4	16	0.285
STS score (%) 4.1(2.7- 4.2(2.8- 4.5(2.7- 6.2(4.1- <0.001	COPD (%)	22	1.1	14	10	0.203
STS score (%) 4.1(2.7- 4.2(2.8- 4.5(2.7- 6.2(4.1- <0.001	NYHA class IV (%)	15	17	20	20	0.842
6.9) 6.7) 7.4) 8.9)	STS score (%)	4.1(2.7-	4.2(2.8-	4.5(2.7-	6.2(4.1-	< 0.001
		6.9)	6.7)	7.4)	8.9)	

Table 2: Baseline imaging parameters according to right ventricle volume

	Q1	Q2	Q3	Q4	p-value
	(<59	(59-69	(69-86	$(>86 \text{ ml/m}^2)$	
	ml/m^2)	ml/m^2)	ml/m^2)		
				n=81	
	n=80	n=81	n=81		
		CT			
Right ventricle volume index	51.2(47-	63(60.6-	74.4(71.5-	99.7(92.1-	< 0.001
(ml/m ²)	54.6)	66.2)	78.5)	117.6)	
Right atrial volume index	41.1(36.6-	47.1(42.5-	61.5(50.6-	90.6(70.6-	< 0.001
(ml/m^2)	47.2)	60.5)	75.9)	105.1)	
Left atrial volume index	56(46-	57.1(48.8-	67.9(58.8-	76.2(64.8-	< 0.001
(ml/m^2)	62.1)	69.2)	82)	88.9)	
Left ventricle volume index	43.9(38.6-	58.4(51.4-	65(56.2-74)	84.6(70.2-	< 0.001
(ml/m^2)	55.8)	68.8)	,	102.7)	
Left ventricle mass index	82.3(68.5-	85.9(73.1-	85.8(73.8-	97.1(87-114)	< 0.001
(gr/m^2)	97.7)	102.1)	103.7)	4.1	(0),
		Echocardiograp	ohy	20,0	
Aortic valve area index	0.37(0.33-	0.37(0.31-	0.37(0.32-	0.34(0.27-	0.030
(cm^2/m^2)	0.45)	0.45)	0.42)	0.41)	
Aortic valve peak gradient	81.4(70.7-	72(60-95.3)	71.9(62-	72.1(57.8-	0.010
(mmHg)	98)		90.9)	82.3)	
Aortic valve mean gradient	51.8(41.8-	44.9(37-59)	43.1(37.8-	42.6(35.8-	0.004
(mmHg)	61.8)		54.3)	48.7)	
Left ventricle ejection	60(60-	60(55-60)	60(55-61.7)	53.9(39.6-	< 0.001
fraction (%)	64.7)			60.2)	
Interventricular septum (mm)	13(12-15)	13(12-14)	13(11-14)	12(11-14)	0.106
E/e' ratio	21.5(15.2-	22.1(14.3-	21.4(16.9-	22.5(17.6-	0.189
-07.	28.1)	27.1)	29.3)	33.5)	
E/A ratio	0.69(0.61-	0.76(0.59-	0.96(0.72-	2(1.22-2.73)	< 0.001
60.	0.83)	0.92)	1.25)		
Left atrial volume index	39.5(32.1-	37.4(32.7-	47.6(39.5-	50.8(43.6-	< 0.001
(ml/m^2)	48.7)	48.5)	59.2)	60.6)	
Systolic pulmonary artery	35(33.6-	38(31-46.4)	42(33-55)	52(41.3-	< 0.001
pressure (mmHg)	41)			64.4)	
Mitral regurgitation	1.3	2.5	1.2	9.9	0.032
≥moderate (%)					

Table 3: Association of right ventricle volume indices with 1-year mortality according to quartiles

	HR (95% CI)	p-value					
	Univariable						
Q2	1.02 (0.21-5.03)	0.986					
Q3	2.29 (0.59-8.87)	0.229					
Q4	3.74 (1.04-13.40)	0.043					
	Propensity score adjusted: Clinical parameters						
Q2	0.91 (0.23-3.66)	0.896					
Q3	1.20 (0.35-4.19)	0.773					
Q4	1.50 (0.46-4.90)	0.504					
Propensity score adjusted:							
Clinical and echocardiographic parameters							
Q2	0.86 (0.20-3.68)	0.837					
Q3	0.95 (0.24-3.80)	0.944					
Q4	1.41 (0.36-5.57)	0.623					

 $\frac{17}{23}$ *Q1 is regarded as the reference group

[‡] Interventricular septum, left ventricle ejection fraction, aortic valve area index, aortic valve gradients, left atrial volume index, E/e, E/A, systolic pulmonary artery pressure, mitral regurgitation.


[†] Age, gender, body mass index, hypertension, diabetes mellitus, hyperlipidaemia, peripheral vascular disease, coronary artery disease, prior myocardial infarction, prior coronary artery bypass graft, prior valve surgery, permanent pacemaker, atrial fibrillation, CVA/TIA, renal dysfunction, dialysis, COPD, NYHA class IV, STS score, medical center.


Table 4: Association of right ventricle volume indices with 1-year mortality according to percentiles

Right Ventricle	Upp	er 25 th	Upper 15 th		Upper 5 th	
Volume Index	percentiles (>83		percentiles (>96		percentiles (>120	
	$m1/m^2$; n=81) vs		$m1/m^2$; n=48) vs		$m1/m^2$; n=16) vs	
	low	er 75 th	low	er 85 th	low	er 95 th
	perce	entiles	perce	entiles	perce	entiles
	HR (95%	p-	HR (95%	p-	HR (95%	p-
	CI)	value	CI)	value	CI)	value
Univariable	2.28 (1.10-	0.027	2.76	0.012	4.70 (1.80-	0.002
	4.75)		(1.25-		12.40)	
			6.09)			
Propensity score	1.41 (0.63-	0.407	1.55	0.300	4.61 (1.73-	0.002
adjusted:	3.34)		(0.68-		12.32)	
clinical [†]			3.52)			-0
parameters					. 2.6	
Propensity score	1.51 (0.65-	0.332	1.92	0.134	2.82 (1.02-	0.045
adjusted:	3.51)		(0.82-		7.78)	
clinical† and			4.49)		10,	
echocardiographic [‡]			A. A			
parameters			1100	9,		


[†] Age, gender, body mass index, hypertension, diabetes mellitus, hyperlipidaemia, peripheral vascular disease, coronary artery disease, prior myocardial infarction, prior coronary artery bypass graft, prior valve surgery, permanent pacemaker, atrial fibrillation, CVA/TIA, renal dysfunction, dialysis, COPD, NYHA class IV, STS score, medical center.

[‡] Interventricular septum, left ventricle ejection fraction, aortic valve area index, aortic valve gradients, left atrial volume index, E/e, E/A, systolic pulmonary artery pressure, mitral regurgitation.





Disclaimer: As a public service to our readership, this article -- peer reviewed by the Editors of EuroIntervention - has been published immediately upon acceptance as it was received. The content of this article is the sole responsibility of the authors, and not that of the journal



Disclaimer: As a public service to our readership, this article -- peer reviewed by the Editors of EuroIntervention - has been published immediately upon acceptance as it was received. The content of this article is the sole responsibility of the authors, and not that of the journal

Supplemental Table 1: Pre-procedural surgical risk according to right ventricular volume

RV volume index	Low risk	Intermediate risk	High risk	Low-Intermediate risk
percentile/quartile	STS<4%	STS 4-8%	STS≥8%	STS<8%
Q1	47.5	38.8	13.8	86.2
Q2	46.9	40.7	12.3	87.7
Q3	44.4	35.8	19.8	80.2
Q4	23.5	46.9	29.6	70.3
Upper 15 th percentile	29.2	35.4	35.4	64.6
Upper 5 th percentile	18.8	50	31.3	68.7

